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Prospective randomized efficacy of ultrasound-
guided foam sclerotherapy compared with
ultrasound-guided liquid sclerotherapy in the
treatment of symptomatic venous malformations
Takashi Yamaki, MD, Motohiro Nozaki, MD, Hiyoyuki Sakurai, MD, Masaki Takeuchi, MD,
Kazutaka Soejima, MD, and Taro Kono, MD, Tokyo, Japan
Objective: To compare the clinical outcome between ultrasound-guided foam sclerotherapy (UGFS) and ultrasound-
guided liquid form sclerotherapy (UGLS) in patients with venous malformations (VM).
Methods: Eighty-nine patients with symptomatic VM were treated with ultrasound-guided sclerotherapy. There were 22
males and 67 females with mean age of 14.5 years. The sclerosing agents used were 1% polidocanol (POL) or 10%
ethanolamine oleate (EO). POL was injected predominantly into smaller, superficial lesions, whereas EO was used for
large, deeper lesions. Foam sclerosing solution was provided using Tessari’s method. Patients were randomized to receive
either UGFS or UGLS. Post-sclerotherapy surveillance was done at 6 months after last session using duplex ultrasound.
Findings obtained by duplex scanning were divided into four groups: (1) disappeared group: the venous space was
occluded and was totally shrunk; (2) partially recanalized group: the venous space was partially recanalized and was
partially shrunk; (3) totally recanalized group: the venous space was totally recanalized and returned at the same size; and
(4) worsened group: the venous space was totally recanalized and became worse.
Results: Forty-nine patients were treated with UGFS and the remaining 40 were treated with UGLS. There were no
significant differences in age and men:women ratio. There was no significant difference in the anatomic distribution of
VMs between the two groups. The amount of POL was significantly smaller in patients who were treated with UGFS
(P  .022). Similarly, there was a significant reduction in the use of EO in patients treated with UGFS (P  .005). The
proportion of VM with total disappearance and partial recanalization was significantly higher in patients treated with
UGFS (P  .002). No major complications related to sclerotherapy were encountered in both groups.
Conclusions: These findings suggest that UGFS could have greater promise compared with UGLS in the treatment of
VMs. (J Vasc Surg 2008;47:578-84.)The symptoms of congenital venous malformations
(VMs) are related to size and distribution, however, throm-
bosis, swelling and pain are commonly observed. The le-
sions grow in muscles, nerves and blood vessels, and are
difficult to delineate. Aggressive excision of VMs can lead
to significant loss of motor function, nerve damage, or
massive bleeding in patients with extensive involvement.
Therefore, the treatment of VMs still remains a matter of
debate.1 Injection sclerotherapy has now been accepted as a
less invasive alternative, and good midterm results have
been obtained using liquid detergent sclerosing form.2
However, VMs with extensive involvement often require
stronger sclerosing agents and multiple sessions of sclero-
therapy since inappropriate therapy and significant recana-
lization can always lead to recurrence. Numerous sclerosing
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578agents have been developed but none of them were ideal or
absolutely safe for the treatment of venous disorders.
Recently, administration of new sclerosing foam has
been introduced by Cabrerra Garrido, predominantly for
the treatment of varicose veins of lower extremities3 and
appeared to have the advantage of causing more severe
damage on the intima compared with the liquid form.
However, few studies have been reported on the use of
sclerosing foam for the treatment of symptomatic VMs.3-7
Therefore, we conducted this study to determine efficacy
and durability of foam sclerotherapy compared with liquid
sclerotherapy in the treatment of VMs.
MATERIALS AND METHODS
Patients
Between January 2001 and December 2006, 89 pa-
tients with consecutive, symptomatic extratruncular venous
defect predominance were treated with ultrasound-guided
sclerotherapy in the Department of Plastic and Reconstruc-
tive Surgery at Tokyo Women’s Medical University. The
patients comprised of 22 males and 67 females, ranging in
age from 1 to 62 years (mean 14.5 years). As most patients
with VMs cannot be completely cured of all manifestations
of their problem, a goal was set for each patient before
treatment began.4 Treatment session was stopped when the
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improvement was expected.
Preoperative evaluation
The diagnosis of VMs was established by demonstrat-
ing non-pulsatile blood flow and venous space using duplex
ultrasound (LOGIQ 500MD, GE Medical Systems, Mil-
waukee,Wis). Magnetic resonance imaging sequences were
also reviewed to document the location and size of VMs.
Identification of the existence of patent deep veins was
confirmed by compression ultrasound in patients who had
VMs in the lower extremity. Venous reflux in the lateral
marginal venous collector in patients with Klippel-Trenaunay
syndrome (KTS) was also confirmed by duplex ultrasound.
Following Hamburg classification, patients were di-
vided into three categories: those with localized or exten-
sive subcutaneous lesions (limited VMs), those with intra-
muscular infiltrations (infiltrating VMs), and those with
complex-combined VMs which involve both extensive sub-
cutaneous and intramuscular lesions.8,9
Exclusion criteria included patients who underwent
any operative procedure including excision of the VMs and
ligation or stripping of the refluxing lateral marginal venous
collector in patients with KTS. The presence of pulsatile
flow indicates the presence of a strong arterial component
suggesting hemangioma and arterial venous malforma-
tions, and these lesions were also excluded from the study.
Ultrasound-guided sclerotherapy
This was a randomized controlled trial of ultrasound-
guided foam sclerotherapy (UGFS) vs ultrasound-guided
liquid sclerotherapy (UGLS) in the treatment of VMs. A
portable ultrasound with 5 to 10 MHz 38-mm linear array
transducer (SonoSite 180 plus, SonoSite Inc, Bothell,
Wash) was used for ultrasound-guided sclerotherapy. The
sclerosing solution used in this study was 1% polidocanol
(POL; Aethoxysklerol, Kaigen, Osaka, Japan) or 10% eth-
anolamine oleate (EO; Oldamin, Takeda Pharmaceutical,
Osaka, Japan). In general, POLwas injected predominantly
into smaller, superficial lesions,whereasEOwasused for large,
deeper lesions. The volume injected and the total number of
sessions depended on the size and distribution of the VMs.
However, the maximum dose of injected sclerosants did not
exceed 1ml/kg for POL and 0.4ml/kg for EO per session.
Sclerosant of higher concentration such as 3% POL was not
used because the amount of solution is extremity-limited
especially in infants. The study protocol and consent forms
were approved by the local institutional review board (IRB).
Ultrasound-guided foam sclerotherapy (UGFS). The
sclerosing foam was produced by Tessari’s method using
POL or EO with the liquid-to-air ratio of 1:4.10,11 Two
syringes were attached by a three-way stopcock, and one
syringe was filled with either POL or EO, and another
with the air. The stable sclerosing foam was obtained by
mixing them through multiple passages between the two
syringes. The venous space was identified intraopera-
tively by duplex scanning, and then venous flow was
confirmed again by pulse Doppler mode. A 20-gaugeplastic needle (JELCO PLUS, Smith Medical Japan Ltd,
Tokyo, Japan) was inserted into the venous space under the
ultrasound visualization, and aspiration of the blood con-
firmed its intraluminal position. After fine plastic tubing
filled with normal saline was attached to the needle, a 10 ml
syringe containing sclerosing foam was connected, and
sclerosing foam was infused slowly. The ultrasound moni-
toring assured intravascular placement of the sclerosing
solution. After the treatment session, compression dressing
was applied for promoting endosclerosis.4 The compres-
sion was maintained for 3 days (Fig 1).
Ultrasound-guided liquid sclerotherapy (UGLS).
Likewise, the venous space was identified intraoperatively
by duplex scanning in B-mode, and then venous flow was
confirmed in pulse Doppler mode in patients who had
UGLS. After a 20-gauge plastic needle was inserted into
the venous space under visualization with duplex scanning,
fine plastic tubing filled with normal saline was attached to
the needle. Several needles were inserted in the same man-
ner, with the number of needles depending on the extent of
venous malformations. The iodinated contrast material was
mixed with either POL or EO with the ratio of 1:1 to
visualize the injected liquid under fluoroscopy. The com-
pression dressing was applied after sclerotherapy and main-
tained for 3 days (Fig 2).
Post-sclerotherapy follow-up
Post-sclerotherapy surveillance was done at 6 months
after last session using duplex ultrasound. Findings ob-
tained by relatively short-term follow-up were divided into
four groups: (1) disappeared group: the venous space was
occluded and was totally shrunk; (2) partially recanalized
group: the venous space was partially recanalized and was
partially shrunk; (3) totally recanalized group: the venous
space was totally recanalized and returned at the same size;
and (4) worsened group: the venous space was totally
recanalized and became worse.
Statistical analysis
All data were analyzed using StatView for Windows
(Version 5.0, SAS Institute Inc, Cary, NC). Wilcoxon
nonparametric rank sum test and 2 analysis or Fisher exact
test were used to evaluate differences between the groups of
patients. Statistical significance was defined as P  .05.
RESULTS
Table I summarizes the baseline characteristics of the
two study groups. Of 89 patients, 49 patients were treated
with UGFS and remaining 40 were treated with UGLS.
Successful needle placement, repositioning, and ultrasound-
monitored foam injection or image-monitored injection of
the mixture was accomplished in all cases without compli-
cation. There were no significant differences in age and
men:women ratio. The most common type of VMs in
UGFS was infiltrating VMs that accounted for 74% of the
patients. Similarly, in the UGLS, proportion of infiltrating
VMs was the most predominant (78%). Patients with lim-
ited and complex-combined VMs are not common in this
e of t
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VMs between the two groups. The most common location
of VM in UGFS was head and neck region, followed by
upper extremity, and lower extremity region (51%, 19%,
and 14%, respectively). Similarly, in the UGLS group, head
and neck was involved in 42% of the patients, 35% had
Fig 1. Ultrasound-guided foam sclerotherapy (UGFS)
demonstrated by ultrasound. D, Complete disappearanclower extremity and 10% had upper extremity involvement.There was no significant difference in the anatomic distri-
bution of VMs between the groups.
Fig 3 shows the amount of sclerosing solution admin-
istered per session. The mean use of POL was 1.4 ml
(range: 0.5-7.0 ml) for UGFS group and 3.4 ml (range:
0.5-7.0 ml) for UGLS group, and there was a significant
efore treatment. B, After treatment. C, Venous space
he venous malformations.. A, Bdifference in the amount of sclerosing solution between the
der fl
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1.7 ml (range: 0.5-6.0 ml) for UGFS group and 3.8 ml
(range: 0.5-10.0 ml) for UGLS group, and the injected
amount of EO was significantly larger in patients who
Fig 2. Ultrasound-guided liquid sclerotherapy (UGLS)
the iodinated contrast material mixed with sclerosant unreceived UGLS (P  .0005).Table II shows the total treatment sessions of ultrasound-
guided sclerotherapy. In UGFS group, 63% of the patients
had only one session. Similarly, in the UGLS group, 58% of
the patients had only one session. On the contrary, 37% of
efore treatment. B, After treatment. C, Visualization of
uoroscopy.. A, Bthe patients with UGFS group required sequential staged
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sessions. Similarly, in UGLS group, 42% of the patients
required multiple sessions, and 2.5% of patients required
greater than five sessions.
Table III shows the findings obtained by duplex scan-
ning 6 months after last session. Follow-up ultrasound
demonstrated no residual venous space in 45% of patients
with UGFS group and 25% with UGLS group. Similarly,
45% of the patients with UGFS group and 15% of the
patients with UGLS group showed partial recanalization
Table I. Baseline characteristics of the study patients
UGFS
(n  49)
UGLS
(n  40) P value
Mean age 16.2  15.5 12.8  8.4 .315
Gender (male) 14 (28.6%) 9 (22.5%) .515
Type of VMs
Infiltrating 36 (73.5%) 31 (77.5%) .661
Limited 8 (16.3%) 6 (15.0%) .864
Complex-combined 5 (10.2%) 3 (7.5%) .657
Distribution of VMs
Head and neck 25 (51.0%) 17 (42.5%) .423
Upper extremity 7 (14.3%) 4 (10%) .541
Trunk 7 (14.3%) 4 (10%) .541
Lower extremity 9 (18.4%) 14 (35.0%) .075
Upper extremity 7 (14.3%) 4 (10%) .541
Genitalia 1 (2.0%) 1 (2.5%) .884
UGFS, Ultrasound-guided foam sclerotherapy; UGLS, ultrasound-guided
liquid sclerotherapy; VMs, venous malformations.
Fig 3. Amount of sclerosants injected. UGFS, Ultrasound-guided
foam sclerotherapy; UGLS, Ultrasound-guided liquid sclerotherapy;
POL, 1% polidocanol; EO, 10% ethanolamine oleate.
Table II. Number of treatment sessions
Sessions UGFS (n  49) UGLS (n  40)
1 31 (63.3%) 23 (57.5%)
2 10 (20.4%) 14 (35%)
3 3 (6.1%) 2 (5%)
4 4 (8.2%) 0 (0%)
More than 5 1 (2%) 1 (2.5%)
UGFS, Ultrasound-guided foam sclerotherapy; UGLS, ultrasound-guided
liquid sclerotherapy.with duplex ultrasound. The proportion of VMs with totaldisappearance and partial recanalization was significantly
higher in patients treated withUGFS group (P .002). On
the contrary, 10% of the patients treated with UGFS
showed total recanalization 6 months after last session.
Similarly, in UGLS group, 30% of the patients demon-
strated complete recanalization and returned at the same size.
Eight percent of patients treated with UGLS showed total
recanalization and became worse after treatment. Successful
results were obtained in patients with limited lesions using
either UGFS or UGLS. However, in patients with infiltrating
and complex-combined lesions, UGFS gave better results.
Table IV shows the early complications related to
ultrasound-guided sclerotherapy. Pain was the most com-
mon complication, but this was resolved within a week.
After treatment sessions, each patient demonstrated an
Table III. Outcome of the ultrasound-guided
sclerotherapy
UGFS
(n  49)
UGLS
(n  40) P value
Disappeared 22 (44.9%) 10 (25.0%)
Infiltrating 15 (30.6%) 9 (22.5%)
Limited 6 (12.2%) 1 (2.5%)
Complex-combined 1 (2.1%) 0 (0%)
Partially recanalized 22 (44.9%) 15 (37.5%)
Infiltrating 18 (36.7%) 10 (25.0%)
Limited 2 (4.1%) 5 (12.5%)
Complex-combined 2 (4.1%) 0 (%)
Subtotal 44 (89.8%) 25 (62.5%) .002
Totally recanalized 5 (10.2%) 12 (30%)
Infiltrating 3 (6.1%) 11 (27.5%)
Limited 0 (0%) 0 (0%)
Complex-combined 2 (4.1%) 1 (2.5%)
Worsened 0 (0%) 3 (7.5)
Infiltrating 0 (0%) 1 (2.5%)
Limited 0 (0%) 0 (0%)
Complex-combined 0 (0%) 2 (5.0%)
Subtotal 5 (10.2%) 15 (37.5%)
Total 49 (100%) 40 (100%)
UGFS, Ultrasound-guided foam sclerotherapy; UGLS, ultrasound-guided
liquid sclerotherapy.
Table IV. Complications of the ultrasound-guided
sclerotherapy
UGFS (n  49) UGLS (n  40)
Pain 44 (89.8%) 32 (80%)
Marked swelling 40 (81.6%) 29 (72.5%)
Epidermal necrosis 1 (2%) 1 (2.5%)
Cutaneous necrosis 0 (0%) 1 (2.5%)
Hemoglobinuria 2 (4.1%) 4 (10%)
Renal failure 0 (0%) 1 (2.5%)
Allergic reactions 0 (0%) 0 (0%)
Superficial thrombophlebitis 0 (0%) 0 (0%)
Deep vein thrombosis 0 (0%) 0 (0%)
Pulmonary embolism 0 (0%) 0 (0%)
Stroke 0 (0%) 0 (0%)
UGFS, Ultrasound-guided foam sclerotherapy; UGLS, ultrasound-guided
liquid sclerotherapy.immediate swelling and inflammatory reaction, which re-
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 3 Yamaki et al 583quired 1-2 weeks to subside. But no patients required
corticosteroid to decrease inflammatory reaction. Hemo-
globinuria was less common in this study. However, one
patient treated with UGLS with the use of EO, required
administration of haptoglobin for severe macroscopic he-
moglobinuria. One patient developed acute renal failure
with the use of EO, and recovered within 1 week by
infusion of K-free fluid and diuretics. Epidermal necrosis
was seen in one patient receiving UGFS and one patient
receiving UGLS. Cutaneous necrosis was found in one pa-
tient, but no further surgical procedure was necessary. No
other serious complications, such as allergic reactions, deep
vein thrombosis, pulmonary embolism, or cerebral infarct.
DISCUSSION
Vascular malformations are errors of morphogenesis
and consist of abnormal channels linked by normal endo-
thelium. In 1982, Mulliken and Glowacki divided vascular
malformations into high flow and low flow vascular malfor-
mations.12 Among the latter, VMs can be most commonly
found. Although there is no generally accepted classifica-
tion, they include focal, multifocal, and diffuse forms.13
Focal lesions may be intramuscular, cutaneous, or mucosal
and usually consist of collections of abnormal interconnect-
ing channels or spaces. Diffuse venous malformations in-
volve multiple tissue layers including muscle, subcutaneous
fat, skin, and sometimes bone. On the contrary, the Ham-
burg classification, which is also well accepted, describes
five types of vascular malformations.8,9 The Hamburg clas-
sification is excellent with minimum confusion because the
terminology provides substantial information on the basis of
embryologic development. Of these, type 2, predominately
venous defects can be subclassified as truncular or extratrun-
cular, either of these. The terms “infiltrated form” and “lim-
ited form” are basic morphological conceptions for extratrun-
cularVMs.The infiltratingVMs show invasion in neighboring
tissues (eg, muscles, bones, glands, and parenchymatous or-
gans) and are associated with the most difficult therapeutic
problem. The limited form, on the other hand, demonstrates
expansive growth, which alleviates significantly its treatment.
VMs often involve multiple contiguous anatomic struc-
tures, and the treatment of VMs remains problematic.
Aggressive surgical intervention often results in significant
loss of motor function and nerve damage when important
structures are sacrificed. Indeed, surgical excisions are often
not possible because of functional and anatomic limita-
tions. Moreover, incomplete surgical removal of VMs often
results in recurrence. For this reason, percutaneous injec-
tion sclerotherapy has been advocated as an effective alter-
native to surgery. A small volume of sclerosing solution can
obliterate large saccular venous malformations because the
blood flow is extremely low and multiple small injections
provide adequate inflammatory response.14
Various sclerosants have been used for the treatment of
VMs. Absolute alcohol has been widely used for symptom-
atic VMs, and considered to give the lowest recurrence
rate.15,16 Svendsen et al used alcohol, and reported excel-
lent or good results in 84% of the patients.16 Yakes et alused absolute alcohol in patients with symptomatic vascular
malformations in whom previous treatment had failed and
found that 95% of the patients showed persistent occlu-
sion.17 Lee et al described the treatment of congenital
VMs with the use of alcohol and obtained the immediate
success rate of the sclerotherapy in 92%.18 Absolute
alcohol is thus effective but destructive, and there are some
complications reported using alcohol. Lee reported 9 cases
with ischemic bullae, 2 with tissue fibrosis, 2 with tissue
necrosis, 1 with deep vein thrombosis, 1 with pulmonary
embolism, and 5 with nerve palsy in 98 sessions of alcohol
sclerotherapy in 30 patients.18 Berenguer et al showed one
patient who had transient bradycardia during the alcohol
sclerotherapy.1 Yakes and Baker reported four episodes of
cardiac arrest during sclerotherapy with alcohol.19 Maison
et al studied the relationship between the serum alcohol
level and the amount of alcohol administered, and found
that patients who receive up to 1.0 ml/kg ethanol during
embolization or sclerotherapeutic procedures may have ele-
vated serum ethanol levels that could put them at risk of
respiratory depression, cardiac arrhythmias, seizures, rhabdo-
myolysis, and hypoglycemia.20 Ethanol should be injected
only after contrast injection has confirmed appropriate place-
ment of the cannula or catheter in the malformation.13
The sodium tetradecyl sulfate (STS) and POL are de-
tergent sclerosants that have been also widely used for the
treatment of VMs. Like ethanol, these drugs damage the
endothelial cells, resulting in thrombosis and fibrosis.
Thrombosis occurs more slowly than with ethanol, and
there is probably a greater tendency for recanalization. As
with ethanol, the cannula position should be confirmed
with contrast medium injection or ultrasonography before
injection of sclerosant, as arterial injection causes severe
tissue damage. However, these drugs are not potent scle-
rosants as ethanol. Siniluoto et al reported excellent or
good results in 68% of the patients with the use of STS.21
They concluded that they might use alcohol if treatment
with STS failed. Berenguer et al discussed the experience
with the use of absolute alcohol and STS, and they used STS
for smaller, superficial malformations, and applied alcohol for
larger, deeper malformations.1 Complications related to the
use of these drugs are less frequently compared with ethanol.
De Lorimier reported anaphylaxis using STS.14 There has
been only one report of a cardiovascular complication using
POL.22 EO is also used for CVMs, and effective result has
been also reported with the use of EO.23,24 EO is a salt of an
unsaturated fatty acid and has been commonly used for the
treatment of esophageal and gastric varices as a sclerosing
agent because it has excellent thrombosing properties.
Injection into varices leads to thrombogenesis as a
result of chemical damage to the vascular wall. However,
some degree of nonspecific red blood cell hemolysis may
occur with its use. To prevent renal damage caused by
EO-induced hemolysis, administration of haptoglobin may
be necessary to protect against renal damage.25
After the introduction of foam form of sclerosing solu-
tion, foam sclerotherapy rapidly gained its popularity in the
treatment of primary valvular insufficiency of the lower ex-
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sclerosant for the treatment of VMs. Historically, Orbach first
described the macrobubble foam preparation with sclerosing
solution in 1950.26 Using his technique, however, only 20%
of the sclerosant was transformed into foam with bubbles of
relatively large and irregular caliber, and foam sclerotherapy
did not become popular till mid 1990s after the introduction
of new methods of transforming sclerosing solutions. There
have been several different methods reported in the produc-
tion of a foam form.3,11,27 In 2000, Tessari reported a new
method for the production of foam with two syringes con-
nected with a three-way stopcock, and it has been widely
accepted in producing a stable foam.11 Yamaki et al applied
ultrasound-guidedPOL-foam sclerotherapy for the treatment
of symptomatic VMs of the face and found significant reduc-
tion of the VMs without any adverse event.4 Pascarella et al
also used POL-foam in 14 patients with VMs and found the
use of POL-foam to be effective, essentially pain-free, and
durable in the short term.6 In general, limited lesions are easily
treated by UGFS (Fig 1, A and B). This type of lesion can be
treated on an outpatient basis without anesthesia. Complex-
combined VMs, however, are difficult to treat effectively
because injected sclerosant can directly enter the circulation
(Fig 2, A and B). In these cases, sclerotherapy is useful for
superficial components but is not fully effective for deep
components. In this study, limited lesions can be treated
with single session of UGFS. However, multiple treatment
sessions are almost always required in patients with infiltrat-
ing VMs with extensive involvement.
CONCLUSION
This study indicated that UGFS with the use of POL or
EO is safe and effective in the treatment of symptomatic
VMs. The advantage of foam sclerosant includes the possibil-
ity of reducing the amount of necessary sclerosing solutions as
well as the concentration with an acceptably low rate of
adverse events. These findings suggest that UGFS could have
greater promise compared with UGLS in the treatment of
VMs. In recent years, much progress has been made in the
treatment of a variety of venous conditions using UGFS.
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